CLX

Business profile & competitive position

The Clorox Company operates in the Consumer Defensive sector under the Household & Personal Products industry. It is a multinational manufacturer and marketer of consumer and professional products, reporting fiscal 2026 net sales of $6.7 billion and employing roughly 9,200 people across about 25 countries that sell into roughly 95 markets. Consumer brands include Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, while the professional line sells under Purell, CloroxPro, and Clorox Healthcare.

Margin and return data tell a mixed story. The company reported a net margin of 8.7%, positive for a staples business, which normally signals some degree of brand pricing power and scale in categories where private-label competition is constant. However, the reported ROE is -1,893.5%. That extreme negative figure is not explained by losses at the net-income line; rather, it almost certainly reflects a deeply negative or very small equity base, potentially driven by cumulative share repurchases, write-downs, or high liabilities. Because shareholders’ equity appears thin or negative, ROE is not a useful moat signal for Clorox right now. Investors should focus instead on the stable margin, the breadth of the brand portfolio, and the recent expansion into professional health and hygiene, where scale and customer relationships matter more than book-value-based returns.

Financial posture

Clorox currently trades with a market capitalization of $10.5 billion and a trailing P/E ratio of 18.1. The P/E sits at a moderate premium to many diversified staples names, reflecting the market’s willingness to pay for cash-flow stability and brand equity. The beta is 0.57, confirming that the stock historically moves roughly half as much as the broader market—a common trait for defensive consumer names.

That defensiveness is reinforced by the 8.7% net margin, but the balance-sheet distortion captured in the -1,893.5% ROE is a material caveat. A negative equity base can limit financial flexibility and magnify leverage ratios, so anyone evaluating Clorox should pair the P/E and margin profile with a close look at debt covenants, goodwill from acquisitions, and the path to rebuilding book equity. The stock price at the time of this snapshot is $87.19, with the 50-day EMA at $88.64 and RSI near 52.8, a neutral reading that neither confirms overbought nor oversold conditions.

Strategic priorities & outlook

The company’s most recent 10-K frames its near-term agenda around the IGNITE strategy, which is built on four choices: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio. Execution is being supported by a new enterprise resource planning (ERP) system and a broader digital transformation intended to drive long-term efficiencies across supply chain, digital commerce, innovation, and brand building.

Operationally, management says it will invest in strong brands, strategic digital capabilities, and a streamlined operating model to create a more resilient company capable of delivering consistent, profitable growth. A key priority is the integration of GOJO Industries, acquired in April 2026, which expands Clorox’s health and hygiene holdings and deepens its business-to-business footprint in professional and institutional markets.

The 10-K also flags real headwinds. Fiscal 2026 brought declines in organic sales and earnings, with diluted EPS down 26%, partly because macro-economic pressures and ERP-transition timing had pulled some sales forward into fiscal 2025. Customer concentration is another risk: Walmart represented 26% of consolidated FY2026 net sales, and the five largest customers accounted for about half of net sales. Separately, the Glad bags and wraps venture with Procter & Gamble expired on January 31, 2026, requiring Clorox to purchase P&G’s 20% interest; Glad retained core intellectual property licenses on a royalty-free basis.

Macro & geopolitical exposure

As a Household & Personal Products company, Clorox faces macro exposures common in the staples space: commodity inputs such as resins, pulp, chemicals, and energy; freight and logistics costs; and packaging inflation. Margins can compress when these input costs rise faster than price increases can be pushed through retailers. The company’s presence in approximately 25 countries and 95 markets also creates currency translation risk, particularly if the U.S. dollar strengthens against currencies where it books overseas revenue.

Regulatory risk is inherent in household cleaning and personal-care products. In the United States, products with antimicrobial or disinfectant claims fall under EPA oversight, while personal-care and cosmetic items face FDA and FTC labeling and marketing rules. Any tightening of chemical-safety standards or disclosure requirements can raise compliance costs. Customer concentration compounds these pressures: with Walmart alone generating 26% of sales, pricing negotiations and inventory shifts at a handful of mega-retailers can have an outsized effect on results.

Recent developments

Over the four trading days ending October 26, 2026, Clorox was referenced only in dividend-themed coverage rather than in company-specific operational news. On October 25, 2026, 247wallst.com published “Whirlpool’s Dividend Collapse Is a Warning for These 3 High-Yield Stocks,” which included Clorox in the discussion. On October 24, 2026, fool.com listed “5 Top Dividend Stocks Yielding 5% or More to Buy Right Now for Passive Income.” On October 23, 2026, Seeking Alpha published both “Dividend Champion, Contender, And Challenger Highlights: Week October 25” and “The Dividend Aristocrats Ranked By Quality Scores (October 2026).”

This cluster of headlines suggests income-focused investors are watching Clorox amid a broader reassessment of payout sustainability across consumer-staples names. It does not, however, provide new operational or financial information beyond what is already in the 10-K and the earnings record.

Earnings behavior & post-earnings drift

Clorox has delivered a solid earnings record over the last eight quarters, beating the market’s real expectation in 6 of 8 reports, for a 75% beat rate. The average earnings surprise over that span was 9.6%. The average 5-day price move following those reports has been +1.67%, classified as an upward post-earnings drift.

Looking at the most recent four quarters shows a more volatile pattern. On August 3, 2026, the company earned $1.66 against an estimate of $1.64 (a 1.2% beat), and the stock rose 6.52% the next day and 9.61% over the next five sessions. On April 30, 2026, Clorox beat with $1.64 versus $1.55 (5.8% surprise), yet the stock sold off 9.67% the next day and was down 4.49% over five days, an example of a “sell the news” reaction even on a beat. The February 3, 2026 report missed by 2.8% ($1.39 vs. $1.43), but the stock gained 2.43% the next day and 5.63% over five days. Finally, on November 3, 2025, a 3.9% beat ($0.85 vs. $0.818) produced a 1.17% next-day gain and a -4.08% five-day drift.

The next scheduled report is November 2, 2026, after the market close, with the market’s real expectation at $1.07 EPS. While the long-term beat rate and positive average drift are notable, the wide single-report dispersion means past drift statistics are only one input among many.

For a deeper dive into how sell-side and institutional models are interpreting these fundamentals, margin dynamics, and the upcoming November 2, 2026 report, readers should review the full institutional verdict alongside their own due diligence.